2,032,680 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Norges Bank

Norges Bank acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,032,680 shares of the biopharmaceutical company’s stock, valued at approximately $662,837,000. Norges Bank owned 1.55% of Alnylam Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $243,000. Mutual of America Capital Management LLC raised its position in Alnylam Pharmaceuticals by 673.9% in the first quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company’s stock valued at $3,684,000 after purchasing an additional 11,881 shares during the period. Cetera Investment Advisers lifted its stake in Alnylam Pharmaceuticals by 68.1% during the first quarter. Cetera Investment Advisers now owns 8,017 shares of the biopharmaceutical company’s stock worth $2,165,000 after purchasing an additional 3,247 shares in the last quarter. HB Wealth Management LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth $208,000. Finally, LPL Financial LLC boosted its position in shares of Alnylam Pharmaceuticals by 11.3% during the first quarter. LPL Financial LLC now owns 20,679 shares of the biopharmaceutical company’s stock worth $5,584,000 after buying an additional 2,107 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Evercore ISI increased their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. The Goldman Sachs Group boosted their price target on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Finally, Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $482.17.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of the business’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the transaction, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 78,328 shares of company stock worth $35,705,793. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ:ALNY opened at $451.27 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm’s 50 day moving average price is $455.81 and its 200 day moving average price is $396.74. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a market cap of $59.62 billion, a price-to-earnings ratio of -182.70 and a beta of 0.30.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.